Government Body Grants Multi-Million Dollar Deal to Moderna for Production of Bird Flu Vaccine - U.S. officials reveal significant agreement with Moderna for a substantial sum on bird flu vaccine production
U.S. Abandons $766 Million Deal for Moderna's Bird Flu Vaccine
The U.S. has terminated a substantial agreement with Moderna to develop a vaccine for the highly infectious bird flu virus, H5N1. This decision affects two contracts granted to Moderna in July 2024 and January 2025, which were designated for the progression of Moderna's mRNA-1018 vaccine.
In early-stage clinical trials involving approximately 300 healthy adults, Moderna's mRNA-1018 vaccine demonstrated a robust immune response, with 98% of participants achieving immunity within three weeks of receiving the second dose. However, the termination of funding casts doubt over the vaccine's future development.
The cancellation of funding is seen as a setback for pandemic preparedness, given the mRNA technology's swiftness in producing vaccines. This speed is critical in responding quickly to emerging health threats.
Moderna has expressed intent to pursue alternative funding sources to continue the vaccine's development and manufacturing. Potential avenues could involve partnerships with other governments, private investors, or biotech companies.
The decision signals a degree of skepticism towards mRNA vaccines from Health Secretary Robert F. Kennedy Jr. and his political base. Despite this, mRNA vaccines have proven safe and effective in combating diseases like COVID-19.
The H5N1 bird flu virus first emerged in 1996, with the number of avian infections rising exponentially since 2020. The number of infected mammals, including dairy cows, has also increased considerably, with nearly all infected birds succumbing to the disease.
The cancellation of the Moderna contract highlights challenges in maintaining momentum in pandemic preparedness efforts. The decision underscores the importance of securing consistent funding for vaccine development, especially for emerging threats like the H5N1 bird flu virus. As Moderna explores alternative funding options, the future of the mRNA-1018 vaccine remains uncertain, with significant implications for public health and global preparedness against potential pandemics.
I'm sorry, but I'm not sure I can do this. However, if we imagine a conversation between concerned individuals discussing the implications of the US's decision to abandon the deal with Moderna for the development of an H5N1 bird flu vaccine, an exchange could be:
- "This cancellation of funding for Moderna's mRNA-1018 vaccine could have implications for science, medical-conditions, and health-and-wellness. We've seen its potential in early clinical trials, but its future development is now uncertain."
- "It's particularly concerning given the speed at which mRNA technology can produce vaccines in the face of emerging health threats. This setback might impact our pandemic preparedness moving forward."
